Zalicus Inc.
245 First Street
Third Floor
Cambridge
Massachusetts
02142
United States
Tel: 617-301-7000
Fax: 617-301-7010
Website: http://www.zalicus.com/
Email: information@zalicus.com
About Zalicus Inc.
Zalicus (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain and immuno-inflammatory diseases and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective Ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com. Zalicus is a public company with 40 employees.253 articles about Zalicus Inc.
-
EPIRUS Biopharmaceuticals And Zalicus Inc. Complete Merger - Combined Company Will Trade As EPIRUS Biopharmaceuticals
7/15/2014
-
Zalicus Inc. And EPIRUS Biopharmaceuticals Agree Zalicus Stockholders To Own 19 Percent Of Combined Company Post-Merger
6/25/2014
-
Zalicus Inc. Licenses Sodium Channel Pain Modulation Program
6/18/2014
-
Zalicus Inc. Announces Closing Of CHTS Service Business Sale To Horizon Discovery Group
6/2/2014
-
Zalicus Inc. Updates Progress On Z944 Clinical Development
5/22/2014
-
Zalicus Inc. Reports Financial Results For The First Quarter 2014
5/9/2014
-
Boston-Based EPIRUS Biopharmaceuticals Reels In $36 Million Series B, Will Merge With Zalicus Inc. In All-Stock Deal
4/16/2014
-
Zalicus Inc.To Present At American Association for Cancer Research 2014 Annual Meeting
4/1/2014
-
Zalicus Inc. Reports Financial Results For The Fourth Quarter And Year-End 2013
3/13/2014
-
Zalicus Inc. Drops Pain Drug After Phase 2 Clinical Trials Fail; Stock Plumments -71.60% at 10:12AM ET on Monday
11/11/2013
-
Zalicus Inc. Reports Financial Results for the Third Quarter 2013
11/4/2013
-
Zalicus Inc. Announces Positive Results of Z944 Phase 1b Clinical Study in Pain
11/1/2013
-
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus Medical Incorporated, Merit Medical Systems, Inc., Invacare Corporation, and Zalicus Inc.
10/30/2013
-
Zalicus Inc. Regains Compliance With NASDAQ Listing Requirements
10/15/2013
-
Zalicus Inc. Announces 1-for-6 Reverse Stock Split
10/3/2013
-
Zalicus Inc.’ Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia
9/27/2013
-
Zalicus Inc. Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain
9/9/2013
-
Zalicus Inc. to Present at the Rodman & Renshaw 15th Annual Global Investment Conference
9/3/2013
-
Zalicus Inc. Completes Patient Enrollment in Two Phase 2 Clinical Studies of Z160 for Chronic Neuropathic Pain
9/3/2013
-
Zalicus Inc. Reports Financial Results for the Second Quarter 2013
8/1/2013